Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1491-1498

  Jain, S ^a   Cohen, J ^b   Ward, M M ^a   Kornhauser, N ^a   Chuang, E ^a   Cigler, T ^a   Moore, A ^a   Donovan, D ^a   Lam, C ^a   Cobham, M V ^a   Schneider, S ^a   Hurtado Rua S M ^a   Benkert, S ^c   Mathijsen Greenwood, C ^a   Zelkowitz, R ^a,d   Warren, J D ^a   Lane, M E ^a   Mittal, V ^a   Rafii, S ^a   Vahdat, L T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d NORWALK HOSPITAL   (United States)

Author keywords

Breast cancer; Endothelial progenitor cells; Tetrathiomolybdate

Indexed keywords

AROMATASE INHIBITOR; CERULOPLASMIN; PROTON PUMP INHIBITOR; TAMOXIFEN; TETRATHIOMOLYBDIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COPPER DEPLETION; DEPLETION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; ENDOTHELIAL PROGENITOR CELL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SULFUR BURPS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 84878467452     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds654     Document Type: Article

References (39)

1. O'Shaughnessy J, Vukelja S, Moiseyenko V et al. Results of a large, phase III trial of Xeloda/taxotere combination therapy versus taxotere monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2000; 53: abstract 381.
2. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
3. Hernandez-Aya LF, Chavez-Macgregor M, Lei X et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 2011; 29: 2628-2634.
4. Wo JY, Chen K, Neville BA et al. Effect of very small tumor size on cancerspecific mortality in node-positive breast cancer. J Clin Oncol 2011; 29: 2619-2627.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
6. Gao D, Nolan DJ, Mellick AS et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008; 319: 195-198.
7. Weidner N, Semple J, Welch W. Tumor angiogenesis and metastasis-correlation in invasive breast cancer. N Engl J Med 1991; 324: 1-8.
8. Iruela-Arispe M, Dvorak H. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Hemostasis 1997; 78: 672-677.
9. Gao D, Nolan D, McDonnell K et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009; 1796: 33-40.
10. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
11. Pitteri SJ, Kelly-Spratt KS, Gurley KE et al. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 2011; 71: 5090-5100.
12. Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
13. Erler JT, Bennewith KL, Cox TR et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15: 35-44.
14. Jain S, Ward MM, O'Loughlin J et al. Incremental increase in VEGFR1 hematopoietic progenitor cells and VEGFR2 endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. Breast Cancer Res Treat 2012; 132: 235-242.
15. Badet J, Soncin F, Guitton J et al. Specific binding of angiogenin to calf pulmonary artery endothelial cells. Proc Natl Acad Sci USA 1989; 86: 8427-8431.
16. Brem S, Zagzag D, Tsanaclis A et al. Inhibition of angiogenesis and tumor growth in the brain: suppression of endothelial cell turnover by penicillamine and depletion of copper, an angiogenic cofactor. Am J Pathol 1990; 137: 1121-1142.
17. Juarez JC, Betancourt OJ, Pirie-Shepherd SR et al. Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase. Clin Cancer Res 2006; 12: 4974-4982.
18. Hassouneh B, Islam M, Nagel T et al. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 2007; 6: 1039-1045.
19. Lowndes SA, Harris AL. The role of copper in tumour angiogenesis. J Mammary Gland Biol Neoplasia 2005; 10: 299-310.
20. Pan Q, Kleer CG, van Golen KL et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002; 62: 4854-4859.
21. Marttila-Ichihara F, Auvinen K, Elima K et al. Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b+ myeloid cells into tumors. Cancer Res 2009; 69: 7875-7883.
22. Erler JT, Bennewith KL, Nicolau M et al. Lysyl oxidase is essential for hypoxiainduced metastasis. Nature 2006; 440: 1222-1226.
23. Finney L, Mandava S, Ursos L et al. X-ray fluorescence microscopy reveals largescale relocalization and extracellular translocation of cellular copper during angiogenesis. Proc Natl Acad Sci USA 2007; 104: 2247-2252.
24. Alvarez HM, Xue Y, Robinson CD et al. Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science 2010; 327: 331-334.
25. Gartner EM, Griffith KA, Pan Q et al. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs 2009; 27: 159-165.
26. Donate F, Juarez JC, Burnett ME et al. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer 2008; 98: 776-783.
27. Pan Q, Rosenthal DT, Bao L et al. Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland. Clin Cancer Res 2009; 15: 7441-7446.
28. Brewer G, Dick D, Grover K et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 2000; 6: 1-11.
29. Redman BG, Esper P, Pan Q et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003; 9: 1666-1672.
30. Pass HI, Brewer GJ, Dick R et al. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 2008; 86: 383-389.
31. Adjuvant! Online [Internet]. New York: Association of Cancer Online Resources, Inc.; c2000-01 [updated 16 May 2002; cited 1 May 2012]. Available from http://www.adjuvantonline.com.
32. Brewer G, Dick R, Yuxbasiyan-Gurkin V et al. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 1991; 48: 42-47.
33. Rody A, Karn T, Liedtke C et al. A clinically relevant gene signature in triple-negative and basal-like breast cancer. Breast Cancer Res 2011; 13: R97.
34. von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
35. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
36. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
37. Moore MA, Hattori K, Heissig B et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann NY Acad Sci 2001; 938: 36-47.
38. Kang H, Watkins G, Parr C et al. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005; 7: 402-410.
39. Rafii S, Heissig B, Hattori K. Efficient mobilization and recruitment of marrowderived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 2002; 9: 631-641.